These nanoconjugates, when administered intravenously, selectively targeted CXCR4+ cancer cells, inducing their selective depletion and regression of stablished metastases in colorectal cancer models [111] and a potent blockade of tumor dissemination in mice models of AML [244, 245] and diffuse large B-cell lymphoma (DLBCL) [247]. The gene discussed is CXCR4; the disease is diffuse large B-cell lymphoma.